These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 35792393)

  • 21. Innate and adaptive immunity to SARS-CoV-2 and predisposing factors.
    Shen J; Fan J; Zhao Y; Jiang D; Niu Z; Zhang Z; Cao G
    Front Immunol; 2023; 14():1159326. PubMed ID: 37228604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta.
    Fröba M; Große M; Setz C; Rauch P; Auth J; Spanaus L; Münch J; Ruetalo N; Schindler M; Morokutti-Kurz M; Graf P; Prieschl-Grassauer E; Grassauer A; Schubert U
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021.
    Bui NN; Lin YT; Huang SH; Lin CW
    Infect Genet Evol; 2022 Jan; 97():105164. PubMed ID: 34848355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic Measures for the Novel Coronavirus: A Review of Current Status and Future Perspective.
    Shahverdi M; Darvish M
    Curr Mol Med; 2021; 21(7):562-572. PubMed ID: 33272178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of SARS-CoV-2 infection on modulating innate immunity and strategies of combating inflammatory response for COVID-19 therapy.
    Wang Y; Wu M; Li Y; Yuen HH; He ML
    J Biomed Sci; 2022 May; 29(1):27. PubMed ID: 35505345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. When RING finger family proteins meet SARS-CoV-2.
    Cai C; Tang YD; Zheng C
    J Med Virol; 2022 Jul; 94(7):2977-2985. PubMed ID: 35257387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options.
    Chakraborty C; Sharma AR; Sharma G; Bhattacharya M; Lee SS
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):4016-4026. PubMed ID: 32329877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection.
    Bhatti JS; Bhatti GK; Khullar N; Reddy AP; Reddy PH
    Mol Neurobiol; 2020 Nov; 57(11):4856-4877. PubMed ID: 32808122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The battle between host and SARS-CoV-2: Innate immunity and viral evasion strategies.
    Zhang S; Wang L; Cheng G
    Mol Ther; 2022 May; 30(5):1869-1884. PubMed ID: 35176485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
    Patil AM; Göthert JR; Khairnar V
    Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure of Nonstructural Protein 1 from SARS-CoV-2.
    Clark LK; Green TJ; Petit CM
    J Virol; 2021 Jan; 95(4):. PubMed ID: 33234675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune response to SARS-CoV-2 variants: A focus on severity, susceptibility, and preexisting immunity.
    Alefishat E; Jelinek HF; Mousa M; Tay GK; Alsafar HS
    J Infect Public Health; 2022 Feb; 15(2):277-288. PubMed ID: 35074728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Innate Immune Response and Inflammasome Activation During SARS-CoV-2 Infection.
    Islamuddin M; Mustfa SA; Ullah SNMN; Omer U; Kato K; Parveen S
    Inflammation; 2022 Oct; 45(5):1849-1863. PubMed ID: 35953688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 within-host diversity of human hosts and its implications for viral immune evasion.
    Xi B; Zeng X; Chen Z; Zeng J; Huang L; Du H
    mBio; 2023 Aug; 14(4):e0067923. PubMed ID: 37273216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2 ORF8: A Rapidly Evolving Immune and Viral Modulator in COVID-19.
    Arduini A; Laprise F; Liang C
    Viruses; 2023 Mar; 15(4):. PubMed ID: 37112851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19.
    van de Leemput J; Han Z
    Mol Cell Biol; 2021 Aug; 41(9):e0018521. PubMed ID: 34124934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uncovering Novel Viral Innate Immune Evasion Strategies: What Has SARS-CoV-2 Taught Us?
    Tay DJW; Lew ZZR; Chu JJH; Tan KS
    Front Microbiol; 2022; 13():844447. PubMed ID: 35401477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential Drug Strategies to Target Coronaviruses.
    Sarkar K; Sil PC
    Adv Exp Med Biol; 2021; 1352():111-124. PubMed ID: 35132597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.